352 related articles for article (PubMed ID: 36093095)
1. Biological effects and regulation of IGFBP5 in breast cancer.
Dittmer J
Front Endocrinol (Lausanne); 2022; 13():983793. PubMed ID: 36093095
[TBL] [Abstract][Full Text] [Related]
2. IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.
Neuzillet Y; Chapeaublanc E; Krucker C; De Koning L; Lebret T; Radvanyi F; Bernard-Pierrot I
BMC Cancer; 2017 Sep; 17(1):636. PubMed ID: 28882129
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to identify control mechanisms for insulin-like growth factor 1 receptor phosphorylation.
Tian D; Mitchell I; Kreeger PK
BMC Syst Biol; 2016 Feb; 10():15. PubMed ID: 26861122
[TBL] [Abstract][Full Text] [Related]
4. Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis.
Leyh B; Dittmer A; Lange T; Martens JW; Dittmer J
Oncotarget; 2015 Nov; 6(36):39307-28. PubMed ID: 26515727
[TBL] [Abstract][Full Text] [Related]
5. An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression.
Wyszynski A; Hong CC; Lam K; Michailidou K; Lytle C; Yao S; Zhang Y; Bolla MK; Wang Q; Dennis J; Hopper JL; Southey MC; Schmidt MK; Broeks A; Muir K; Lophatananon A; Fasching PA; Beckmann MW; Peto J; Dos-Santos-Silva I; Sawyer EJ; Tomlinson I; Burwinkel B; Marme F; Guénel P; Truong T; Bojesen SE; Nordestgaard BG; González-Neira A; Benitez J; Neuhausen SL; Brenner H; Dieffenbach AK; Meindl A; Schmutzler RK; Brauch H; ; Nevanlinna H; Khan S; Matsuo K; Ito H; Dörk T; Bogdanova NV; Lindblom A; Margolin S; Mannermaa A; Kosma VM; ; ; Wu AH; Van Den Berg D; Lambrechts D; Wildiers H; Chang-Claude J; Rudolph A; Radice P; Peterlongo P; Couch FJ; Olson JE; Giles GG; Milne RL; Haiman CA; Henderson BE; Dumont M; Teo SH; Wong TY; Kristensen V; Zheng W; Long J; Winqvist R; Pylkäs K; Andrulis IL; Knight JA; Devilee P; Seynaeve C; García-Closas M; Figueroa J; Klevebring D; Czene K; Hooning MJ; van den Ouweland AM; Darabi H; Shu XO; Gao YT; Cox A; Blot W; Signorello LB; Shah M; Kang D; Choi JY; Hartman M; Miao H; Hamann U; Jakubowska A; Lubinski J; Sangrajrang S; McKay J; Toland AE; Yannoukakos D; Shen CY; Wu PE; Swerdlow A; Orr N; Simard J; Pharoah PD; Dunning AM; Chenevix-Trench G; Hall P; Bandera E; Amos C; Ambrosone C; Easton DF; Cole MD
Hum Mol Genet; 2016 Sep; 25(17):3863-3876. PubMed ID: 27402876
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner.
Hermani A; Shukla A; Medunjanin S; Werner H; Mayer D
Cell Signal; 2013 Jun; 25(6):1395-402. PubMed ID: 23499909
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice.
Salih DA; Tripathi G; Holding C; Szestak TA; Gonzalez MI; Carter EJ; Cobb LJ; Eisemann JE; Pell JM
Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4314-9. PubMed ID: 15010534
[TBL] [Abstract][Full Text] [Related]
8. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer.
Li X; Cao X; Li X; Zhang W; Feng Y
Cancer Sci; 2007 Oct; 98(10):1592-6. PubMed ID: 17651454
[TBL] [Abstract][Full Text] [Related]
9. PKNOX2 suppresses gastric cancer through the transcriptional activation of IGFBP5 and p53.
Zhang L; Li W; Cao L; Xu J; Qian Y; Chen H; Zhang Y; Kang W; Gou H; Wong CC; Yu J
Oncogene; 2019 Jun; 38(23):4590-4604. PubMed ID: 30745575
[TBL] [Abstract][Full Text] [Related]
10. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas.
Wang H; Arun BK; Wang H; Fuller GN; Zhang W; Middleton LP; Sahin AA
Breast J; 2008; 14(3):261-7. PubMed ID: 18373644
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factors in human breast cancer.
Ellis MJ; Jenkins S; Hanfelt J; Redington ME; Taylor M; Leek R; Siddle K; Harris A
Breast Cancer Res Treat; 1998; 52(1-3):175-84. PubMed ID: 10066081
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of insulin-like growth factor binding protein-5 during N-(4-hydroxyphenyl)retinamide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells: regulation by CCAAT/enhancer-binding protein.
Samuel W; Kutty RK; Vijayasarathy C; Pascual I; Duncan T; Redmond TM
J Cell Physiol; 2010 Sep; 224(3):827-36. PubMed ID: 20583135
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the quantitative balance between insulin-like growth factor (IGF)-1 ligand, receptor, and binding protein levels to predict cell sensitivity and therapeutic efficacy.
Tian D; Kreeger PK
BMC Syst Biol; 2014 Aug; 8():98. PubMed ID: 25115504
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor binding protein 5: Diverse roles in cancer.
Waters JA; Urbano I; Robinson M; House CD
Front Oncol; 2022; 12():1052457. PubMed ID: 36465383
[TBL] [Abstract][Full Text] [Related]
15. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action.
McGuire WL; Jackson JG; Figueroa JA; Shimasaki S; Powell DR; Yee D
J Natl Cancer Inst; 1992 Sep; 84(17):1336-41. PubMed ID: 1379645
[TBL] [Abstract][Full Text] [Related]
16. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.
Ghoussaini M; Edwards SL; Michailidou K; Nord S; Cowper-Sal Lari R; Desai K; Kar S; Hillman KM; Kaufmann S; Glubb DM; Beesley J; Dennis J; Bolla MK; Wang Q; Dicks E; Guo Q; Schmidt MK; Shah M; Luben R; Brown J; Czene K; Darabi H; Eriksson M; Klevebring D; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Lambrechts D; Thienpont B; Neven P; Wildiers H; Broeks A; Van't Veer LJ; Th Rutgers EJ; Couch FJ; Olson JE; Hallberg E; Vachon C; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Peto J; Dos-Santos-Silva I; Gibson L; Nevanlinna H; Muranen TA; Aittomäki K; Blomqvist C; Hall P; Li J; Liu J; Humphreys K; Kang D; Choi JY; Park SK; Noh DY; Matsuo K; Ito H; Iwata H; Yatabe Y; Guénel P; Truong T; Menegaux F; Sanchez M; Burwinkel B; Marme F; Schneeweiss A; Sohn C; Wu AH; Tseng CC; Van Den Berg D; Stram DO; Benitez J; Zamora MP; Perez JI; Menéndez P; Shu XO; Lu W; Gao YT; Cai Q; Cox A; Cross SS; Reed MW; Andrulis IL; Knight JA; Glendon G; Tchatchou S; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Lindblom A; Margolin S; Teo SH; Yip CH; Lee DS; Wong TY; Hooning MJ; Martens JW; Collée JM; van Deurzen CH; Hopper JL; Southey MC; Tsimiklis H; Kapuscinski MK; Shen CY; Wu PE; Yu JC; Chen ST; Alnæs GG; Borresen-Dale AL; Giles GG; Milne RL; McLean C; Muir K; Lophatananon A; Stewart-Brown S; Siriwanarangsan P; Hartman M; Miao H; Buhari SA; Teo YY; Fasching PA; Haeberle L; Ekici AB; Beckmann MW; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Swerdlow A; Ashworth A; Orr N; Schoemaker MJ; García-Closas M; Figueroa J; Chanock SJ; Lissowska J; Simard J; Goldberg MS; Labrèche F; Dumont M; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Brauch H; Brüning T; Koto YD; Radice P; Peterlongo P; Bonanni B; Volorio S; Dörk T; Bogdanova NV; Helbig S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Devilee P; Tollenaar RA; Seynaeve C; Van Asperen CJ; Jakubowska A; Lubinski J; Jaworska-Bieniek K; Durda K; Slager S; Toland AE; Ambrosone CB; Yannoukakos D; Sangrajrang S; Gaborieau V; Brennan P; McKay J; Hamann U; Torres D; Zheng W; Long J; Anton-Culver H; Neuhausen SL; Luccarini C; Baynes C; Ahmed S; Maranian M; Healey CS; González-Neira A; Pita G; Alonso MR; Alvarez N; Herrero D; Tessier DC; Vincent D; Bacot F; de Santiago I; Carroll J; Caldas C; Brown MA; Lupien M; Kristensen VN; Pharoah PD; Chenevix-Trench G; French JD; Easton DF; Dunning AM; ;
Nat Commun; 2014 Sep; 4():4999. PubMed ID: 25248036
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the DNA methylation and gene expression of IGFBP5 in breast cancer.
Karabulut S; Kaya Z; Amuran GG; Peker I; Özmen T; Gūllūoḡlu BM; Kaya H; Erzik C; Ōzer A; Akkiprik M
Breast Dis; 2016; 36(4):123-131. PubMed ID: 27612043
[TBL] [Abstract][Full Text] [Related]
18. IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells.
Sureshbabu A; Okajima H; Yamanaka D; Tonner E; Shastri S; Maycock J; Szymanowska M; Shand J; Takahashi S; Beattie J; Allan G; Flint D
J Cell Sci; 2012 Apr; 125(Pt 7):1693-705. PubMed ID: 22328518
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells.
Wang J; Ding N; Li Y; Cheng H; Wang D; Yang Q; Deng Y; Yang Y; Li Y; Ruan X; Xie F; Zhao H; Fang X
Oncotarget; 2015 Aug; 6(24):20636-49. PubMed ID: 26010068
[TBL] [Abstract][Full Text] [Related]
20. The Wilms tumor protein WT1 stimulates transcription of the gene encoding insulin-like growth factor binding protein 5 (IGFBP5).
Müller M; Persson AB; Krueger K; Kirschner KM; Scholz H
Gene; 2017 Jul; 619():21-29. PubMed ID: 28366834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
